4.6 Article

Bone geometry in older adults with subclinical hypothyroidism upon levothyroxine therapy: A nested study within a randomized placebo controlled trial

Journal

BONE
Volume 161, Issue -, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2022.116404

Keywords

Levothyroxine; Subclinical hypothyoroidism; Peripheral quantitative computational tomography; Bone geometry; Volumetric bone density

Funding

  1. Swiss National Science Foundation [SNSF 320030-150025, 320030-172676, 32003B_200606, PZ00P3-167826]
  2. European Union FP7HEALTH-2011 program [278148]
  3. Swiss Heart Foundation
  4. Velux Stiftung [974a]
  5. Swiss Society of Endocrinology and Diabetes
  6. Leenaards Foundation
  7. Vontobel Foundation
  8. European Commission project THYRAGE (Horizon 2020 Research And Innovation Program) [666869]
  9. ZonMw [627001001]
  10. Swiss National Science Foundation (SNF) [32003B_200606] Funding Source: Swiss National Science Foundation (SNF)
  11. H2020 Societal Challenges Programme [666869] Funding Source: H2020 Societal Challenges Programme

Ask authors/readers for more resources

This study investigated the effect of levothyroxine (LT4) therapy on appendicular bone geometry and volumetric density in patients with subclinical hypothyroidism. The results showed that LT4 therapy had no significant effect on bone mass, bone geometry, and volumetric density in older adults with subclinical hypothyroidism.
The effect of levothyroxine (LT4) therapy for subclinical hypothyroidism (SHypo) on appendicular bone geometry and volumetric density has so far not been studied. In a nested study within the randomized, placebocontrolled Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) trial, we assessed the effect of LT4 therapy on bone geometry as measured by peripheral quantitative computed tomography (pQCT). In the TRUST trial, community-dwelling adults aged >= 65 years with SHypo were randomized to LT4 with dose titration vs. placebo with mock titration. We analyzed data from participants enrolled at the TRUST site in Bern, Switzerland who had bone pQCT measured at baseline and at 1 to 2 years follow-up. The primary outcomes were the annual percentage changes of radius and tibia epi- and diaphysis bone geometry (total and cortical crosssectional area (CSA) and cortical thickness), and of volumetric bone mineral density (bone mineral content (BMC) and total, trabecular and cortical volumetric bone mineral density (vBMD)). We performed linear regression of the annual percentage changes adjusted for sex, LT4 dose at randomization and muscle crosssectional area. The 98 included participants had a mean age of 73.9 (+/- SD 5.4) years, 45.9% were women, and 12% had osteoporosis. They were randomized to placebo (n = 48) or LT4 (n = 50). Annual changes in BMC and vBMD were similar between placebo and LT4-treated groups, without significant difference in bone geometry or volumetric bone mineral density changes, neither at the diaphysis, nor at the epiphysis. For example, in the placebo group, epiphyseal BMC (radius) decreased by a mean 0.2% per year, with a similar decrease of 0.5% per year in the LT4 group (between-group difference in %Delta BMC 0.3, 95% CI -0.70 to 1.21, p = 0.91). Compared to placebo, LT4 therapy for an average 14 months had no significant effect on bone mass, bone geometry and volumetric density in older adults with subclinical hypothyroidism. Trial registration: The trial was registered on ClinicalTrials.gov numbers NCT01660126 (TRUST Thyroid trial) and NCT02491008 (Skeletal outcomes).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available